Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895763 | 0.92 | MAPT (0.51) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4895103 | 0.92 | TP53 (0.49) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4903953 | 0.92 | PKM (0.48) | MAPTTP53ALDH1A1SMN1; SMN2AKR1C3 | |
| SCHEMBL4899720 | 0.90 | MAPT (0.52) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4906132 | 0.89 | ALDH1A1 (0.58) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4902977 | 0.88 | MAPT (0.54) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4908345 | 0.87 | MAPT (0.46) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4906182 | 0.87 | MAPT (0.52) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4903854 | 0.87 | ALDH1A1 (0.48) | MAPTALDH1A1SMN1; SMN2AKR1C3MEN1 | |
| SCHEMBL4907671 | 0.86 | ALDH1A1 (0.53) | MAPTLMNAALDH1A1SMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | MAPT 1786/4885TP53 3421/4885LMNA 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.